Skip to Main Content

Paper Details

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
Oncogene
29
2018
EPHB6, ERK, Eph group, GRB2 adapter protein, HER2 receptor, OCT4, RAS, TIC, TIC populations, TICs, TNBC, TNBC cells, Triple-negative breast cancer (TNBC) tumours, breast cancer, epithelial, oestrogen, patient, patients, progesterone, progesterone receptors, receptor tyrosine kinases, slowly proliferating, slowly proliferating tumour-initiating cells, triple, triple-negative breast cancer tumours, tumour, tumour-initiating cells, tumours, tyrosine
Author NameAffiliation
Mohan BabuUniversity of Regina
Tanya FreywaldCollege of Medicine, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive
Frederick S VizeacoumarCollege of Medicine, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive
Alana L WelmHuntsman Cancer Institute, University of Utah
Alana L WelmHuntsman Cancer Institute, University of Utah
Franco J VizeacoumarUniversity of Saskatchewan
Andrew FreywaldCollege of Medicine, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive
  • 1 - 7

Datasets

Release 1.2